These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 29938543)

  • 21. Interleukin-4/interleukin-13 versus interleukin-5: a comparison of molecular targets in biologic therapy for the treatment of severe asthma.
    Wu AY; Sur S; Grant JA; Tripple JW
    Curr Opin Allergy Clin Immunol; 2019 Feb; 19(1):30-37. PubMed ID: 30407206
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
    Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
    Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Treatment of refractory asthma with antibodies].
    Lommatzsch M
    Dtsch Med Wochenschr; 2016 Jun; 141(11):790-3. PubMed ID: 27254629
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of Biological Therapies for Severe Asthma: An Analysis of Suspected Adverse Reactions Reported in the WHO Pharmacovigilance Database.
    Cutroneo PM; Arzenton E; Furci F; Scapini F; Bulzomì M; Luxi N; Caminati M; Senna G; Moretti U; Trifirò G
    BioDrugs; 2024 May; 38(3):425-448. PubMed ID: 38489062
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An evaluation of mepolizumab for the treatment of severe asthma.
    Morjaria JB; Emma R; Fuochi V; Polosa R; Caruso M
    Expert Opin Biol Ther; 2019 Jun; 19(6):491-500. PubMed ID: 31009582
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacokinetic/pharmacodynamic profile of reslizumab in asthma.
    Matera MG; Rogliani P; Calzetta L; Cazzola M
    Expert Opin Drug Metab Toxicol; 2018 Feb; 14(2):239-245. PubMed ID: 29268638
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Monoclonal Antibodies for Treatment of Uncontrolled Eosinophilic Asthma.
    Koski RR; Grzegorczyk KM
    J Pharm Pract; 2020 Aug; 33(4):513-522. PubMed ID: 31046541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative Efficacy of Anti IL-4, IL-5 and IL-13 Drugs for Treatment of Eosinophilic Asthma: A Network Meta-analysis.
    Iftikhar IH; Schimmel M; Bender W; Swenson C; Amrol D
    Lung; 2018 Oct; 196(5):517-530. PubMed ID: 30167841
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term Safety and Efficacy of Reslizumab in Patients with Eosinophilic Asthma.
    Murphy K; Jacobs J; Bjermer L; Fahrenholz JM; Shalit Y; Garin M; Zangrilli J; Castro M
    J Allergy Clin Immunol Pract; 2017; 5(6):1572-1581.e3. PubMed ID: 29122156
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Benralizumab, a Monoclonal Antibody against IL-5Rα, in Uncontrolled Eosinophilic Asthma.
    Khorasanizadeh M; Eskian M; Assa'ad AH; Camargo CA; Rezaei N
    Int Rev Immunol; 2016 Jul; 35(4):294-311. PubMed ID: 27119985
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment Challenges in Severe Eosinophilic Asthma: Differential Response to Anti-IL-5 and Anti-IL-5R Therapy.
    Bakakos A; Rovina N; Bakakos P
    Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921360
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reslizumab in the treatment of inadequately controlled asthma in adults and adolescents with elevated blood eosinophils: clinical trial evidence and future prospects.
    Máspero J
    Ther Adv Respir Dis; 2017 Aug; 11(8):311-325. PubMed ID: 28683596
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Benralizumab in the treatment of severe asthma: design, development and potential place in therapy.
    Pelaia C; Vatrella A; Bruni A; Terracciano R; Pelaia G
    Drug Des Devel Ther; 2018; 12():619-628. PubMed ID: 29606855
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma.
    Agache I; Beltran J; Akdis C; Akdis M; Canelo-Aybar C; Canonica GW; Casale T; Chivato T; Corren J; Del Giacco S; Eiwegger T; Firinu D; Gern JE; Hamelmann E; Hanania N; Mäkelä M; Hernández-Martín I; Nair P; O'Mahony L; Papadopoulos NG; Papi A; Park HS; Pérez de Llano L; Posso M; Rocha C; Quirce S; Sastre J; Shamji M; Song Y; Steiner C; Schwarze J; Alonso-Coello P; Palomares O; Jutel M
    Allergy; 2020 May; 75(5):1023-1042. PubMed ID: 32034960
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on new biologics for intractable eosinophilic asthma: impact of reslizumab.
    Sahota J; Robinson DS
    Drug Des Devel Ther; 2018; 12():1173-1181. PubMed ID: 29780238
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overlapping Effects of New Monoclonal Antibodies for Severe Asthma.
    Domingo C
    Drugs; 2017 Oct; 77(16):1769-1787. PubMed ID: 28948572
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal antibodies for the treatment of refractory asthma.
    Hambly N; Nair P
    Curr Opin Pulm Med; 2014 Jan; 20(1):87-94. PubMed ID: 24275927
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?
    Katsoulis K; Kipourou M; Loukides S
    Expert Opin Biol Ther; 2022 Mar; 22(3):377-384. PubMed ID: 34328380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.